Increase in Lipoprotein (a) levels during COVID-19 hospitalization tied to VTE risk: Study
Netherlands: Results from a pilot study published in the journal Atherosclerosis showed that in patients hospitalized with COVID-19, the levels of lipoprotein(a) increase threefold during hospitalization. And, an increase in Lp(a) levels during the COVID-19 acute phase was strongly linked with venous thromboembolism (VTE) incidence. In contrast to this, the change in the inflammatory biomarkers interleukin (IL)-6 and CRP was not associated with VTE incidence.
In patients with Coronavirus disease 2019 (COVID-19), thrombosis is shown to be a major driver of mortality and adverse outcomes. Hypercoagulability may be related to the cytokine storm associated with COVID-19, which is driven mainly by IL-6. An increase in Lp(a) levels following IL-6 upregulation and Lp(a) has anti-fibrinolytic properties.
Against the above background, Erik S.G. Stroes, University of Amsterdam, Amsterdam, the Netherlands, and colleagues aimed to investigate whether Lp(a) elevation may contribute to the pro-thrombotic state hallmarking COVID-19 patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.